ArticleFrontiers in oncology2025
Radiomics models to predict axillary lymph node metastasis in breast cancer and analysis of the biological significance of radiomic features.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Radiogenomic landscape of the hallmarks of cancer.Biomarker research · 2026Review
- Kinetic and radiomic features on DCE-MRI as a predictor for axillary lymph node metastasis burden in T1 and T2 stage breast cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To explore the effectiveness of radiomics in predicting axillary lymph node metastasis (ALNM) and the relationship between radiomics features and genes. Method: The 379 patients with breast cancer (186 ALNM-positive and 193 ALNM-negative) recruited from three hospitals were divided into the training (n=224), testing (n=96), and validation (n=59) cohorts. The Cancer Imaging Archive-The Cancer Genome Atlas (TCIA-TCGA) group included 107 patients with breast cancer. A total of 1888 intratumoral and peritumoral radiomics features were extracted from DCE-MRI sequences. Radiomics models were established using a multivariate regression algorithm for each region and their combinations. Clinical and combined nomogram models integrating the Radscore with clinical risk factors were constructed. The biological significance of the radiomic features was analyzed by combining the TCIA database. Results: The area under the ROC curve (AUC) of radiomics model in the external validation was 0.760 (95% confidence interval [CI]: 0.626-0.874). The performance of the nomogram combined model (AUC: 0.818; 95% CI:0.702-0.916) surpassed those of both the radiomics and clinical models (AUC: 0.753; 95% CI: 0.630-0.869). Additionally, the DCA results demonstrated the usefulness of the radiomics and nomogram model. Conclusion: MRI-based radiomics has the potential to predict the ALNM status in patients with invasive breast cancer. Additionally, radiogenomic analysis demonstrated a correlation between radiomic features and the immune microenvironment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.